Separate steatosis, hepatitis, and cirrhosis; interpret severity and steroid response; and connect nutrition, alcohol-use treatment, and transplant care.
One patient has a fatty liver and mild AST elevation. Another has jaundice, kidney injury, and an AST of only 160 U/L. The second patient may be much sicker. Aminotransferases describe injury; they do not tell you how much functional reserve remains.
Name the phenotype, assess liver function and complications, and treat alcohol use disorder alongside the liver disease. Prednisolone belongs to a selected severe hepatitis pathway, not to every AST-predominant result.
Fat, inflammation, and scar answer different questions
Alcohol-associated liver disease, or ALD, includes overlapping forms of injury rather than a mandatory sequence that every patient completes. Steatosis is intracellular fat accumulation, often macrovesicular. It may cause hepatomegaly or modest laboratory abnormalities with preserved bilirubin and INR. Fat can improve substantially with sustained abstinence. That reversibility does not prove that coexisting fibrosis is absent. Assess fibrosis risk even when a patient feels well. [1][5]
Alcohol-associated hepatitis, or AH, is a clinical syndrome of recent onset or worsening jaundice after sustained heavy alcohol exposure. Tender hepatomegaly, anorexia, fever, leukocytosis, and deteriorating liver function may accompany it. Histologic steatohepatitis describes fat, cellular injury, and inflammation under the microscope; it is not synonymous with every clinical AH presentation. AH can occur on top of cirrhosis and can precipitate acute-on-chronic liver failure. [1]
Cirrhosis is architectural distortion by fibrosis and regenerative nodules. A compensated patient has not yet developed major clinical decompensation such as ascites, overt encephalopathy, or variceal hemorrhage. Decompensation changes prognosis and the need for transplant assessment. Normal AST and ALT do not exclude advanced cirrhosis. Portal hypertension may be apparent through splenomegaly, thrombocytopenia, varices, or ascites even when enzyme leakage is minimal. [4]
Read the liver across three different dimensions
Cell injury
AST and ALT reflect leakage from injured cells. They neither identify alcohol as the cause by themselves nor quantify remaining reserve.
Function and systemic risk
Bilirubin, INR, creatinine, sodium, mental status, and their trajectory help reveal impaired excretion, synthesis, kidney function, and whole-patient risk.
Architecture and pressure
Nodular contour, fibrosis assessment, splenomegaly, varices, and ascites reveal structural disease and portal hypertension.
A patient can have serious abnormalities in one dimension with only modest changes in another. Do not use a single enzyme value as a substitute for this combined assessment.
Connect alcohol metabolism to the tissue pattern
Alcohol dehydrogenase converts ethanol to acetaldehyde, and aldehyde dehydrogenase converts acetaldehyde to acetate. Acetaldehyde is reactive and can damage cellular proteins. Chronic exposure also promotes oxidative stress, including through CYP2E1-mediated metabolism. Alcohol metabolism alters cellular redox balance and lipid handling, while inflammatory responses and repeated injury promote fibrosis. The result is more than a fat-storage problem. [6]
On histology, look for macrovesicular steatosis, hepatocyte ballooning, lobular inflammation often rich in neutrophils, and Mallory-Denk bodies. Mallory-Denk bodies are aggregated damaged keratin intermediate filaments in hepatocyte cytoplasm. They are not organisms and are not unique to alcohol. Metabolic steatohepatitis can show the same inclusion, so histology must be interpreted with exposure and the broader clinical picture. [3]
Place zone 3 near the venous end of sinusoidal blood flow
Portal tract. Portal venous and hepatic arterial inflow enters the lobular microcirculation.
Zone 1 → zone 2 → zone 3. Blood travels through sinusoids toward the central vein. Zone 3 is centrilobular, not beside the portal bile duct.
Central vein. Centrilobular injury and pericellular or perisinusoidal fibrosis are characteristic early patterns in adult steatohepatitis.
Fibrosis can surround hepatocytes in a pericellular pattern, then bridge regions and distort the whole liver. The diagram locates the tissue pattern; it does not distinguish alcohol from metabolic disease on its own. [3]
As fibrosis increases resistance to portal flow, portal pressure rises. Collateral veins and varices form, the spleen enlarges, and ascites can develop through portal and systemic circulatory changes. Sarcopenia, infection, withdrawal, and kidney injury further reduce resilience. The biopsy and the bedside therefore describe different levels of the same illness. [4]
Recent jaundice starts an evaluation, not a steroid prescription
Obtain an alcohol history respectfully and concretely. Ask about drink size, frequency, amount, duration, recent reduction or cessation, prior withdrawal, and treatment goals. A US standard drink contains about 14 g of alcohol; actual servings may contain more than one. An exposure history supports the diagnosis but does not excuse skipping viral, biliary, medication-related, ischemic, or autoimmune alternatives. Alcohol and metabolic risk can also coexist. [1][7]
The probable AH pattern summarized in ACG Table 5 includes onset of jaundice within 60 days of heavy alcohol use, summarized there as more than 50 g/day for at least six months, bilirubin above 3 mg/dL, AST in the 50 to 400 U/L range, an AST:ALT ratio above 1.5, and no other cause of acute hepatitis. An uncertain exposure history or competing cause makes the diagnosis less secure. These are a clinical pattern, not a laboratory certification. AST or ALT in the thousands should prompt a search for ischemic injury, acetaminophen toxicity, acute viral hepatitis, or another superimposed process. A ratio above 2 can support the history but is neither necessary nor sufficient. [1]
Assess bilirubin, INR or prothrombin time, albumin, creatinine, electrolytes, blood counts, and mental status. Obtain ultrasound or other indicated imaging to assess biliary obstruction and structural disease. Review drugs and supplements, assess viral risks, and investigate competing causes according to the history. Liver biopsy is reserved for meaningful diagnostic uncertainty when the result would change management; a typical clinical presentation does not require biopsy solely to search for Mallory-Denk bodies. [1]
Fever and leukocytosis may reflect inflammatory AH, infection, or both. Search for infection rather than deciding from fever alone. Obtain appropriate cultures and chest evaluation; perform diagnostic paracentesis when ascites and the clinical setting warrant evaluation for spontaneous bacterial peritonitis. Active bleeding, hypotension, renal dysfunction, and altered mental status need their own assessment. Do not label every confused patient as either withdrawal or hepatic encephalopathy without considering the timing and accompanying findings. [1][4]
ACG identifies an original MELD score above 20 as severe AH for corticosteroid consideration. The treatment evidence and threshold cited here use the original bilirubin, INR and creatinine model, rather than automatically substituting MELD-Na or MELD 3.0. Use a validated calculator and record the version; AST is not an input. Maddrey discriminant function remains a familiar historical tool. Its formula uses 4.6 times the difference between patient and control prothrombin time in seconds, plus bilirubin in mg/dL; 32 or above identifies a traditionally severe group. It does not replace current severity assessment or contraindication screening. [1][2]
For severe AH with adequate diagnostic confidence and no major unresolved contraindication, prednisolone 40 mg daily for a planned four-week course is a commonly used regimen. The potential benefit is chiefly short term; steroids do not repair established cirrhosis and are not indicated for uncomplicated steatosis. Benefit is greatest in the MELD 25 to 39 range. Scores above 50 require especially careful assessment because available observational evidence has not shown benefit in that group. Active uncontrolled infection, gastrointestinal bleeding, severe renal failure, or uncontrolled diabetes may preclude treatment. Eligibility can be reconsidered after a reversible contraindication is adequately controlled. [1]
Before treatment
MELD and clinical assessment ask how severe the illness is and whether steroid exposure is justified and safe enough.
After treatment starts
The Lille score on day 4 or day 7 incorporates response, including bilirubin trajectory. A value above 0.45 identifies nonresponse and supports stopping corticosteroids.
A high admission MELD does not justify continuing an ineffective steroid course. Conversely, a favorable Lille response supports completing the planned course if no new contraindication emerges. Monitor infection, glucose, kidney function, bleeding, and nutrition throughout treatment. A new complication can change the plan even in a responder. [1][2]
The 2024 ACG guideline recommends intravenous N-acetylcysteine as an adjunct to corticosteroids in severe AH, commonly as a five-day infusion course. It is not a replacement for eligibility screening or a proven stand-alone cure. Pentoxifylline is not recommended as routine AH treatment. Failure of medical therapy should prompt assessment for selected early transplantation rather than indefinite steroid exposure. [1][2]
Treat nutrition and alcohol use every day
Malnutrition is common even when body weight appears normal or increased by fluid retention. AH nutrition goals commonly include about 35 kcal/kg/day and 1.2 to 1.5 g/kg/day of protein, individualized with nutrition expertise and an appropriate weight estimate. Use oral supplements when intake is inadequate and enteral support when needed. Frequent meals and a late snack reduce long fasting intervals in cirrhosis. Routine protein restriction worsens muscle loss and is not treatment for hepatic encephalopathy. Monitor electrolytes and refeeding risk in a severely undernourished patient. [1][4]
Provide thiamine and correct identified micronutrient deficiencies. In a patient at risk for Wernicke encephalopathy, use prompt parenteral thiamine; hypoglycemia still requires immediate glucose rather than waiting for thiamine availability. Withdrawal risk must be assessed when alcohol intake stops. Benzodiazepines remain treatment for significant withdrawal, with careful titration and monitoring in liver disease because sedation can worsen encephalopathy. Lorazepam or oxazepam may be preferred when impaired hepatic oxidative metabolism is a concern. [1][8]
Sustained abstinence is the central disease-modifying goal across ALD stages. Offer integrated addiction and hepatology care, motivational and behavioral support, and medication when appropriate. A recommendation to stop drinking without a treatment plan is incomplete. Discuss barriers to access, mental health needs, relapse triggers, and follow-up without punitive language. A return to drinking should prompt renewed support and reassessment. [1]
Medication selection must account for liver stage, kidney function, current opioids, sedation, and patient goals. ACG recommends baclofen as an option in compensated ALD and conditionally suggests acamprosate or naltrexone in that population, with very low certainty for the latter recommendation. Baclofen is used off label for AUD. Acamprosate lacks hepatic metabolism but is contraindicated with creatinine clearance at or below 30 mL/min and requires dose reduction for moderate renal impairment. The 2024 ACG guidance allows naltrexone in compensated disease and advises avoidance in decompensated cirrhosis or liver failure. A subsequent large retrospective cirrhosis cohort found no probable naltrexone-induced liver injury, providing reassuring evidence that deserves specialist consideration without proving safety in every severe presentation. [10] Naltrexone is contraindicated with opioid analgesics or ongoing opioid dependence. Review recent opioid use and the required opioid-free interval before initiation to avoid precipitated withdrawal. [11] Disulfiram should be avoided across ALD because of hepatotoxicity. These are individualized addiction-treatment decisions, not an interchangeable drug list. [1][9]
Plan for cirrhosis and recovery beyond the admission
Patients with cirrhosis need ongoing portal-hypertension assessment, prevention and treatment of decompensation, and hepatocellular carcinoma surveillance. For eligible patients, AASLD recommends liver ultrasound with AFP every six months. Manage ascites, encephalopathy, and variceal risk through the appropriate cirrhosis pathway. Improvement in AST after abstinence does not erase surveillance needs in established cirrhosis. Assess vaccination status, nutrition, muscle function, and coexisting metabolic or viral disease. [4]
Decompensated cirrhosis or severe AH that does not respond to medical treatment warrants consideration of transplant evaluation. Early transplantation is possible for carefully selected patients after multidisciplinary medical and psychosocial assessment. A fixed six-month abstinence interval should not be the sole selection criterion. This is neither an automatic entitlement nor an automatic exclusion; assessment includes recovery potential, engagement in treatment, support, relapse risk, and institutional requirements. [1]
Fat with preserved function calls for alcohol-use care, nutrition, and fibrosis assessment.
Recent jaundice calls for syndrome confirmation, severity scoring, infection evaluation, and exclusion of alternatives.
Severe eligible AH may receive corticosteroids with adjunctive NAC and a day 4 or 7 response plan.
Nonresponse, new hazards, or decompensation requires a revised plan and possible transplant assessment.
Every stage needs continuing treatment of alcohol use disorder.
Separate injury, function, and treatment response
Case 1
Show answer and explanations for case 1
A. Structured alcohol-use treatment, nutrition support, and fibrosis assessment (Best answer)
Preserved function and steatosis support treating the exposure and assessing chronic risk, not assuming severe AH.
B. Start prednisolone because AST exceeds ALT (Why this does not fit)
She has steatosis with preserved function and no jaundice syndrome; this is not severe AH requiring steroid consideration.
C. Recommend a low-protein diet to reduce hepatic workload (Why this does not fit)
Protein restriction is not ALD treatment and can worsen malnutrition without treating alcohol exposure.
D. Observe liver tests alone without assessing alcohol-use treatment needs (Why this does not fit)
Enzyme monitoring alone misses disease-modifying AUD care and assessment for coexisting fibrosis.
Takeaway: Steatosis calls for exposure treatment and fibrosis assessment.
